New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT07223125

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times

Summary

This early-stage study is testing an experimental drug called JNJ-89862175 for people with advanced solid tumors that have spread or cannot be removed. The drug is designed to target and kill cancer cells. The main goals are to find a safe dose and to check for side effects. About 360 adults with certain types of lung, kidney, ovarian, or uterine cancer can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED-STAGE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32803, United States
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED-STAGE SOLID TUMORS